Venous thromboembolic disease

Lawrence D. Wagman, Melissa F. Baird, Charles L. Bennett, Paula L. Bockenstedt, Spero R. Cataland, John Fanikos, Patrick F. Fogarty, Samuel Z. Goldhaber, Tejpal S. Grover, William Haire, Hani Hassoun, Suzanne Hutchinson, Mohammad Jahanzeb, Jason Lee, Michael L. Linenberger, Michael M. Millenson, Thomas L. Ortel, Riad Salem, Judy L. Smith, Michael B. StreiffSuresh Vedantham

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Recognizing the increased risk for VTE in cancer patients is the first step in preventing its occurrence and promptly identifying it in these patients. The panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who have no contraindications to this therapy, and also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. After hospital discharge, the panel recommends that patients at high risk for VTE (e.g., patients who have undergone surgery for cancer) continue to receive VTE prophylaxis for up to 4 weeks postoperation. Careful evaluation and follow-up of cancer patients in whom VTE is suspected, and prompt treatment and follow-up for those diagnosed with VTE is recommended after the cancer status of the patient is assessed and the risks and benefits of treatment are considered.

Original languageEnglish (US)
Pages (from-to)716-753
Number of pages38
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number8
StatePublished - Sep 2008


  • Anti-coagulation
  • Cancer
  • Deep venous thrombosis
  • Heparin
  • NCCN Clinical Practice Guidelines
  • Prophylaxis
  • Pulmonary embolism
  • Treatment
  • Venous thromboembolism

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Venous thromboembolic disease'. Together they form a unique fingerprint.

Cite this